CXCR4 and neoplasm: As a consequence, due to its improved CXCR4 targeting in vitro and in vivo, leading to higher tumor/non-tumor ratios compared to [177Lu]PentixaTher, [177Lu]DOTA-r-a-ABA-CPCR4 may have potential as a second generation CXCR4-targeted therapeutic agent and thus will be further evaluated in preclinical dosimetry studies.